News articles about Epizyme (NASDAQ:EPZM) have trended somewhat positive on Thursday, according to Accern. The research group identifies positive and negative news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Epizyme earned a news impact score of 0.11 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 46.9679449980472 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the media headlines that may have effected Accern Sentiment’s scoring:
- Global Mantle Cell Lymphoma Treatment Market 2018 -EpiZyme, Inc., Fate Therapeutics, Inc., Genentech, Inc., Gilead … (truthfuleditor.com)
- Waging Stocks: ION Geophysical Corporation (NYSE:IO), Epizyme, Inc. (NASDAQ:EPZM) (thestreetpoint.com)
- Weekly Epizyme, Inc. (NASDAQ:EPZM) Ratings on Apr 15, 2018 (thecasualsmart.com)
- Epizyme, Inc. (EPZM): Healthcare Stock to Track: (stocksgeeks.com)
- Price to Earnings Ratio Analysis – Epizyme Inc (NASDAQ: EPZM) (stocksmarketcap.com)
A number of research firms have recently issued reports on EPZM. BidaskClub lowered shares of Epizyme from a “buy” rating to a “hold” rating in a report on Tuesday, April 10th. Zacks Investment Research downgraded shares of Epizyme from a “buy” rating to a “hold” rating in a research report on Friday, March 16th. ValuEngine downgraded shares of Epizyme from a “sell” rating to a “strong sell” rating in a research report on Monday, April 9th. Wedbush reaffirmed an “outperform” rating and set a $25.00 price objective (down from $26.00) on shares of Epizyme in a research report on Wednesday, March 14th. Finally, Leerink Swann boosted their target price on shares of Epizyme from $22.00 to $24.00 and gave the stock an “outperform” rating in a research report on Wednesday, March 14th. One analyst has rated the stock with a sell rating, three have given a hold rating and eleven have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $23.50.
Epizyme (NASDAQ:EPZM) last issued its quarterly earnings data on Tuesday, March 13th. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.57) by $0.05. The business’s revenue for the quarter was down 100.0% compared to the same quarter last year. research analysts anticipate that Epizyme will post -2.37 EPS for the current fiscal year.
In other news, COO Matthew Ros sold 72,264 shares of the business’s stock in a transaction on Monday, February 5th. The shares were sold at an average price of $16.63, for a total value of $1,201,750.32. Following the completion of the sale, the chief operating officer now directly owns 74,867 shares in the company, valued at $1,245,038.21. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 21.50% of the stock is currently owned by insiders.
WARNING: This piece was originally reported by Week Herald and is the sole property of of Week Herald. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international trademark and copyright law. The legal version of this piece can be read at https://weekherald.com/2018/04/19/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-epizyme-epzm-stock-price.html.
Epizyme, Inc, a clinical stage biopharmaceutical company, discovers and develops novel epigenetic medicines for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial in elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function,; and Phase Ib/II clinical trial for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer, as well as Phase II clinical trial in adult patients with ovarian cancer.
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.